Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 and GO in Relapsed Refractory AML and HR-MDS
NCT03672539Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2018
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daunorubicin + cytarabine liposome and gemtuzumab ozogamicin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Response Rate at 56 days and Adverse Events at 14 months. Started Nov 2018; status: completed.
02
Drugs
daunorubicin + cytarabine liposomegemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03672539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03672539.